Luxna Biotech
Company Details
Status: Private
Employees: 1-10
Location:
Osaka, Japan
Type:
sample
Technology:
sample
sample
sample
sample
About: Luxna Biotech is a preclinical antisense drug development company based on proprietary modified nucleic acids, unique bridged structure (AmNA, scpBNA, GuNA) and modified DNA (5'-CP) can eliminate phosphorothioated in antisense and siRNA. Currently, better modifications are being discovered that are suitable for applications in neurological diseases that minimize neurotoxicity while maintaining knockdown efficacy in vivo by Gapmer. Based on these findings we developed excellent antisense (ASO) drug discovery platform called “LuxiAPTM” enable to wide therapeutic index for CNS ASO drug. We have several pharmaceutical collaborations and original ASO pipeline including ALS, Spinal cord injury and Hearing loss. We are looking for the partners not only for platform collaboration with pharmaceuticals and biotech but early-stage co-development alliance with our original pipeline.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Luxna Biotech | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.